These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 29290170

  • 21. The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis.
    Synnott PG, Bloudek LM, Sharaf R, Carlson JJ, Pearson SD.
    J Manag Care Spec Pharm; 2020 Mar; 26(3):236-239. PubMed ID: 32105176
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
    Jakubowiak AJ, Campioni M, Benedict Á, Houisse I, Tichy E, Giannopoulou A, Aggarwal SK, Barber BL, Panjabi S.
    J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
    [Abstract] [Full Text] [Related]

  • 23. A Summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
    Otuonye IS, Banken R, Kumar VM, Pearson SD.
    J Manag Care Spec Pharm; 2019 Jun; 25(6):630-634. PubMed ID: 31134864
    [Abstract] [Full Text] [Related]

  • 24. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
    Pelligra CG, Parikh K, Guo S, Chandler C, Mouro J, Abouzaid S, Ailawadhi S.
    Clin Ther; 2017 Oct; 39(10):1986-2005.e5. PubMed ID: 28967482
    [Abstract] [Full Text] [Related]

  • 25. Can We Develop Sustainable and Sharable Cost-Effectiveness Models for Value Assessment in the U.S. Health Care System?
    Chapman RH, Kumar V.
    J Manag Care Spec Pharm; 2019 May; 25(5):521-524. PubMed ID: 31039064
    [Abstract] [Full Text] [Related]

  • 26. The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression.
    Agboola F, Atlas SJ, Touchette DR, Fazioli K, Pearson SD.
    J Manag Care Spec Pharm; 2020 Jan; 26(1):16-20. PubMed ID: 31880219
    [Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
    Narsipur N, Bulla S, Yoo C, Do B, Tran K, Gu D, Zhong L, Wilson L.
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
    [Abstract] [Full Text] [Related]

  • 28. The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.
    Tice JA, Walton SM, Sarker J, Moradi A, Chu JN, Herce-Hagiwara B, Fahim SM, Agboola F, Rind D, Pearson SD.
    J Manag Care Spec Pharm; 2023 May; 29(5):576-581. PubMed ID: 37121251
    [Abstract] [Full Text] [Related]

  • 29. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, Ganguli A, Fendrick AM.
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [Abstract] [Full Text] [Related]

  • 30. The effectiveness and value of aducanumab for Alzheimer's disease.
    Synnott PG, Whittington MD, Lin GA, Rind DM, Pearson SD.
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1613-1617. PubMed ID: 34714106
    [Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
    Jakubowiak AJ, Houisse I, Májer I, Benedict Á, Campioni M, Panjabi S, Ailawadhi S.
    Expert Rev Hematol; 2017 Dec; 10(12):1107-1119. PubMed ID: 29027825
    [Abstract] [Full Text] [Related]

  • 32. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value.
    Agboola F, Atlas SJ, Brouwer E, Carlson JJ, Hansen RN, Herron-Smith S, Nhan E, Rind DM, Pearson SD.
    J Manag Care Spec Pharm; 2022 Jan; 28(1):108-114. PubMed ID: 34949111
    [Abstract] [Full Text] [Related]

  • 33. The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder.
    Tice JA, Whittington MD, Campbell JD, Pearson SD.
    J Manag Care Spec Pharm; 2021 Apr; 27(4):528-532. PubMed ID: 33769860
    [Abstract] [Full Text] [Related]

  • 34. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG.
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [Abstract] [Full Text] [Related]

  • 35. The effectiveness and value of novel treatments for cystic fibrosis.
    Tice JA, Kuntz KM, Wherry K, Seidner M, Rind DM, Pearson SD.
    J Manag Care Spec Pharm; 2021 Feb; 27(2):276-280. PubMed ID: 33506736
    [Abstract] [Full Text] [Related]

  • 36. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR.
    Zeng X, Peng L, Peng Y, Tan C, Wan X.
    Clin Ther; 2020 Feb; 42(2):251-262.e5. PubMed ID: 31973936
    [Abstract] [Full Text] [Related]

  • 37. Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
    Chen CC, Parikh K, Abouzaid S, Purnomo L, McGuiness CB, Hussein M, Wade RL.
    J Manag Care Spec Pharm; 2017 Feb; 23(2):236-246. PubMed ID: 28125372
    [Abstract] [Full Text] [Related]

  • 38. Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value.
    McKenna A, Lin GA, Whittington MD, Nikitin D, Herron-Smith S, Campbell JD, Agboola F, Pearson SD.
    J Manag Care Spec Pharm; 2023 Jul; 29(7):857-861. PubMed ID: 37404068
    [Abstract] [Full Text] [Related]

  • 39. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ, Barton S, Thurgar E, Trevor N.
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [Abstract] [Full Text] [Related]

  • 40. The effectiveness and value of belimumab and voclosporin for lupus nephritis.
    Tice JA, Mandrik O, Thokala P, Fotheringham J, Pearson SD.
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1495-1499. PubMed ID: 34595943
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.